Onyx Pharma Says NCCN Published Update on Treatment Guidelines

From Onyx Pharma ONXX filing: On March 8, 2013, the National Comprehensive Cancer Network, or NCCN, published an update to its treatment guidelines. For the treatment of multiple myeloma, the combination of carfilzomib, lendalidomide and dexamethasone was added to the NCCN guidelines under the category “other regimens” as a therapeutic option for patients who are transplant candidates. Additionally, carfilzomib monotherapy, along with several other agents, was added as an NCCN preferred treatment regimen for salvage therapy. The information in this Form 8-K regarding the NCCN treatment guidelines is also publicly available from the NCCN. This information is being provided as a convenience to investors. Treatment guidelines such as those published by NCCN may, as here, go beyond the uses that have been approved by the FDA.